New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
Baptist GallwitzDept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-05-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/new-treatments-in-the-management-of-type-2-diabetes-a-critical-apprais-peer-reviewed-article-DMSO |
| _version_ | 1797935247722020864 |
|---|---|
| author | Gallwitz B |
| author_facet | Gallwitz B |
| author_sort | Gallwitz B |
| collection | DOAJ |
| description | Baptist GallwitzDept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia. In comparison to sulfonylureas and thiazolidinediones that promote weight gain, DPP-4 inhibitors are weight neutral. Saxagliptin has been approved by the FDA for the US and by the EMEA for Europe in 2009. Clinical trials showed a dose-dependent inhibition of DPP-4 by saxagliptin in doses ranging from 2.5 to 100 mg daily without serious side effects. Type 2 diabetic patients receiving 5 mg to 10 mg saxagliptin once daily had a significant lowering of HbA1c and glycemic parameters along with good tolerability and safety. Saxagliptin has demonstrated a good efficacy for glycemic parameters in various patient populations either in monotherapy or in combination with metformin and other oral antidiabetic drugs as well as a favorable cardiovascular profile. With its high selectivity for DPP-4 and its clinical and cardiovascular profile, saxagliptin is an attractive novel DPP-4 inhibitor.Keywords: type 2 diabetes, diabetes therapy, DPP-4 inhibitors, incretin based therapy, GLP-1, saxagliptin |
| first_indexed | 2024-04-10T18:11:24Z |
| format | Article |
| id | doaj.art-59aefce73bca42f689f11d9de1343e7b |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T18:11:24Z |
| publishDate | 2010-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-59aefce73bca42f689f11d9de1343e7b2023-02-02T10:44:55ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072010-05-01Volume 31171244384New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptinGallwitz BBaptist GallwitzDept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia. In comparison to sulfonylureas and thiazolidinediones that promote weight gain, DPP-4 inhibitors are weight neutral. Saxagliptin has been approved by the FDA for the US and by the EMEA for Europe in 2009. Clinical trials showed a dose-dependent inhibition of DPP-4 by saxagliptin in doses ranging from 2.5 to 100 mg daily without serious side effects. Type 2 diabetic patients receiving 5 mg to 10 mg saxagliptin once daily had a significant lowering of HbA1c and glycemic parameters along with good tolerability and safety. Saxagliptin has demonstrated a good efficacy for glycemic parameters in various patient populations either in monotherapy or in combination with metformin and other oral antidiabetic drugs as well as a favorable cardiovascular profile. With its high selectivity for DPP-4 and its clinical and cardiovascular profile, saxagliptin is an attractive novel DPP-4 inhibitor.Keywords: type 2 diabetes, diabetes therapy, DPP-4 inhibitors, incretin based therapy, GLP-1, saxagliptinhttps://www.dovepress.com/new-treatments-in-the-management-of-type-2-diabetes-a-critical-apprais-peer-reviewed-article-DMSOtype 2 diabetesdiabetes therapyDPP-IV inhibitorsincretin based therapyGLP-1saxagliptin |
| spellingShingle | Gallwitz B New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin Diabetes, Metabolic Syndrome and Obesity type 2 diabetes diabetes therapy DPP-IV inhibitors incretin based therapy GLP-1 saxagliptin |
| title | New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin |
| title_full | New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin |
| title_fullStr | New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin |
| title_full_unstemmed | New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin |
| title_short | New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin |
| title_sort | new treatments in the management of type 2 diabetes a critical appraisal of saxagliptin |
| topic | type 2 diabetes diabetes therapy DPP-IV inhibitors incretin based therapy GLP-1 saxagliptin |
| url | https://www.dovepress.com/new-treatments-in-the-management-of-type-2-diabetes-a-critical-apprais-peer-reviewed-article-DMSO |
| work_keys_str_mv | AT gallwitzb newtreatmentsinthemanagementoftype2diabetesacriticalappraisalofsaxagliptin |